Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone206-325-6086
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/19/2019 (Estimated)
OptionableNot Optionable
Atossa Genetics (NASDAQ:ATOS) Frequently Asked Questions
What is Atossa Genetics' stock symbol?
Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS."
When did Atossa Genetics' stock split? How did Atossa Genetics' stock split work?
Shares of Atossa Genetics reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Genetics stock prior to the reverse split would have 8 shares after the split.
How were Atossa Genetics' earnings last quarter?
Atossa Genetics Inc (NASDAQ:ATOS) announced its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.64) EPS for the quarter, topping the Zacks' consensus estimate of ($0.65) by $0.01. View Atossa Genetics' Earnings History.
When is Atossa Genetics' next earnings date?
What price target have analysts set for ATOS?
2 analysts have issued 1 year price targets for Atossa Genetics' shares. Their forecasts range from $5.00 to $10.00. On average, they expect Atossa Genetics' stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 70.5% from the stock's current price. View Analyst Price Targets for Atossa Genetics.
What is the consensus analysts' recommendation for Atossa Genetics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Genetics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atossa Genetics.
Has Atossa Genetics been receiving favorable news coverage?
Media stories about ATOS stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Atossa Genetics earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are some of Atossa Genetics' key competitors?
Some companies that are related to Atossa Genetics include Dyadic International (DYAI), Tissue Regenix Group (TRX), Shield Therapeutics (STX), ANGLE (AGL), Elite Pharmaceuticals (ELTP), Orgenesis (ORGS), Ergomed (ERGO), Cyclopharm (CYC), Invion (IVX), Aptose Biosciences (APTO), Theralase Technologies (TLT), Processa Pharmaceuticals (PCSA), Iterum Therapeutics (ITRM), Tetraphase Pharmaceuticals (TTPH) and Medicure (MCUJF).
What other stocks do shareholders of Atossa Genetics own?
Who are Atossa Genetics' key executives?
Atossa Genetics' management team includes the folowing people:
- Dr. Steven C. Quay, Chairman, CEO & Pres (Age 68)
- Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 55)
- Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical Affairs
- Dr. Jack Cuzick, Member of Scientific Advisory Board
Who are Atossa Genetics' major shareholders?
Atossa Genetics' stock is owned by many different of retail and institutional investors. Top institutional investors include Virtu Financial LLC (1.24%) and Barclays PLC (0.57%). Company insiders that own Atossa Genetics stock include H Lawrence Remmel and Kyle Guse. View Institutional Ownership Trends for Atossa Genetics.
Which institutional investors are buying Atossa Genetics stock?
ATOS stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Barclays PLC. Company insiders that have bought Atossa Genetics stock in the last two years include H Lawrence Remmel and Kyle Guse. View Insider Buying and Selling for Atossa Genetics.
How do I buy shares of Atossa Genetics?
Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Atossa Genetics' stock price today?
One share of ATOS stock can currently be purchased for approximately $4.40.
How big of a company is Atossa Genetics?
Atossa Genetics has a market capitalization of $24.85 million.
What is Atossa Genetics' official website?
How can I contact Atossa Genetics?
Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected]
MarketBeat Community Rating for Atossa Genetics (NASDAQ ATOS)
MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote "Outperform" if you believe ATOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
